Summit Global Investments Innoviva, Inc. Transaction History

Summit Global Investments

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	SELL	$11.8 - $13.78 $22,903 - $26,746	-1,941 Reduced 1.39%	138,188 $1.83 Million
Q3 2022 Nov 14, 2022	SELL	$11.61 - $15.22 $203,279 - $266,486	-17,509 Reduced 11.11%	140,129 $1.63 Million
Q2 2022 Aug 23, 2022	BUY	$14.32 - $19.88 $345,197 - $479,227	24,106 Added 18.05%	157,638 $2.33 Million
Q1 2022 Apr 29, 2022	SELL	$15.39 - $20.25 $348,860 - $459,027	-22,668 Reduced 14.51%	133,532 $2.58 Million
Q4 2021 Feb 14, 2022	BUY	$15.91 - $18.72 $1.58 Million - $1.86 Million	99,200 Added 174.04%	156,200 $2.69 Million
Q3 2021 Nov 08, 2021	BUY	$13.06 - $17.24 $744,420 - $982,679	57,000 New	57,000 $952,000

228

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.22B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Summit Global Investments, based on Form 13F filings with the SEC.

Stay updated on Summit Global Investments with notifications on news.